LOQTORZI
Growthtoripalimab-tpzi
BLAINJECTIONINJECTABLEPriority Review
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
LOQTORZI (toripalimab-tpzi) is programmed death receptor-1-directed antibody interactions [moa]. Approved for recurrent nasopharyngeal carcinoma. First approved in 2023.
Drug data last refreshed Yesterday
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications (1)
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.